Anti-telomerase cancer therapy: MiRNA-1827 suppresses the expression of Tripeptidyl Peptidase 1 (TPP1) and inhibits cancer progression via down-regulation of its target gene, 24/November/2016, 8.49 am

Anti-metastasis therapy: MiRNA-9600 increases the expression of metastasis suppressor BTG2 and inhibits proliferation, invasion and metastasis of cancer cells via down regulation of its target gene,23/November/2015, 6.06 am
November 24, 2016
Molecular therapy for Metabolic disorders: MiRNA-152 increases (LXR)-α expression, insulin-secreting cell mass and function via down regulation of its target genes, 24/November/2016, 1.27 pm
November 24, 2016
Show all

Introduction: What they say:  

The 1989 Nobel prize winner in Chemistry, Prof. Thomas R. Cech from the BioFrontiers Institute, USA has published a research paper in the 13 December 2012 Nature (492(7428):285-9; and I.F: >42) stating that “The TEL patch of telomere protein TPP1 mediates telomerase recruitment and processivity.”  This study provides mechanistic insights into how TPP1 regulates telomerase function.


What we say

price-100

In connection with this finding,                                   Dr Boominathan, Founder Director-cum-chief scientist of GBMD, reports that: Anti-telomerase cancer therapy: MiRNA-1827 suppresses the expression of Tripeptidyl Peptidase 1 (TPP1) and inhibits cancer progression via down-regulation of its target gene


Significance:

Given that: (1) over 90% human tumors overexpress immortality gene telomerase; (2) cancer causes the highest economic loss compared to all the known causes of death worldwide, there is an urgent need to find: (i) a way to inhibit telomerase activity in human tumors, to increase the efficacy of anticancer therapy;  (ii) a cheaper alternative to the existing expensive drugs; (iii) a side-effect-free natural product-based drug; (iv) a way to effectively treat cancers that are resistant to anti-cancer drugs; and (v) a way to effectively treat and eradicate metastatic progression of cancer.


From Research Findings to Therapeutic opportunity:

This study suggests that MiRNA-1827 , by decreasing the expression of its target gene, it may suppress the expression of Tripeptidyl Peptidase 1 (TPP1). Remarkably, over 90% of the human tumors overexpress the cellular immortality gene telomerase, suggesting that inhibition of its activity may increase the efficacy of anticancer therapy. Taken together, pharmacological formulations encompassing MiRNA-1827  or its activators may be used to treat human cancers that specifically overexpress the cellular immortality gene telomerase. 


Details of the Research findings:

Idea Proposed/Formulated (with experimental evidence) by:

Dr L Boominathan Ph.D.

Amount: $100#

Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/

Undisclosed information: How MiRNA-1827   suppresses the expression of Tripeptidyl Peptidase 1 (TPP1) and telomerase

# Research cooperation


References:

CitationBoominathan, L., Anti-telomerase cancer therapy: MiRNA-1827 suppresses the expression of Tripeptidyl Peptidase 1 (TPP1) and inhibits cancer progression via down-regulation of its target gene, 24/November/2016, 8.49 am,  Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org

Courtesy: When you cite drop us a line at info@genomediscovery.org

Web: http://genomediscovery.org or http://newbioideas.com

Comments are closed.